for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Option Care Health Inc

BIOS.OQ

Latest Trade

3.58USD

Change

0.12(+3.47%)

Volume

204,440

Today's Range

3.44

 - 

3.64

52 Week Range

1.56

 - 

4.14

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.46
Open
3.44
Volume
204,440
3M AVG Volume
22.55
Today's High
3.64
Today's Low
3.44
52 Week High
4.14
52 Week Low
1.56
Shares Out (MIL)
699.64
Market Cap (MIL)
2,420.74
Forward P/E
-34.60
Dividend (Yield %)
--

Next Event

Q3 2019 Option Care Health Inc Earnings Release

Latest Developments

More

BioScrip Announces Shareholder Approval Of Merger With Option Care

BioScrip Reports Qtrly Loss Per Share $0.14

Bioscrip Reports First Quarter 2019 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Option Care Health Inc

Option Care Health, Inc., formerly BioScrip, Inc., incorporated on March 22, 1996, provides home and alternate site infusion services in the United States. The Company provides a range of infusion therapies to patients. It provides care for patients with acute and chronic conditions. Its therapeutic services include anti-infective, Option Care Women’s health, bleeding disorders, heart failure, immunoglobulin, nutrition support, chronic inflammatory disorders and specialized therapies. Its other services include hemophilia care, transplant and pediatrics.

Industry

Healthcare Facilities

Contact Info

3000 Lakeside Dr Ste 300N

+1.312.9402443

https://www.bioscrip.com/

Executive Leadership

Harry M. Jansen Kraemer

Independent Chairman of the Board

John Charles Rademacher

President, Chief Executive Officer, Director

Michael H Shapiro

Chief Financial Officer

Harriet Booker

Chief Operating Officer, Senior Vice President

Robert R. Kampstra

Chief Accounting Officer

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.9K

2017

0.8K

2018

0.7K

2019(E)

1.6K
EPS (USD)

2016

-0.540

2017

-0.580

2018

-0.490

2019(E)

-0.100
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.29
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-9.90
Return on Equity (TTM)
-8.22

Latest News

Latest News

BRIEF-BioScrip Reports Qtrly Loss Per Share $0.12

* QTRLY LOSS PER SHARE $0.12 Source text for Eikon: Further company coverage:

BRIEF-BioScrip Provides Update On Immaterial Financial Statement Corrections

* BIOSCRIP TIMELY FILES ANNUAL FORM 10-K, CONCLUDES ACCOUNTING REVIEW AND PROVIDES UPDATE ON IMMATERIAL FINANCIAL STATEMENT CORRECTIONS

BRIEF-Bioscrip Inc Files For Non Timely 10-K - SEC Filing

* BIOSCRIP INC FILES FOR NON TIMELY 10-K - SEC FILING Source text (http://bit.ly/2pbYT3N) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-BioScrip Reports Q4 Preliminary Net Revenue Of $182.6 Mln

* BIOSCRIP REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-BioScrip Announces Additions To Senior Leadership Team

* BIOSCRIP - ANNOUNCED APPOINTMENTS OF HARRIET BOOKER AS CHIEF OPERATING OFFICER, DANNY CLAYCOMB AS SENIOR VICE PRESIDENT, REVENUE CYCLE MANAGEMENT Source text for Eikon: Further company coverage:

BRIEF-BioScrip can now dispense & administer radicava treatment option for amyotrophic lateral sclerosis

* BioScrip says can now dispense & administer Radicava (edaravone) treatment option for amyotrophic lateral sclerosis approved by U.S. FDA Source text for Eikon: Further company coverage:

BRIEF-Coliseum Capital reports 14.6 pct stake in Bioscrip

* Coliseum Capital Management LLC reports 14.6 percent stake in Bioscrip Inc as of September 7, 2017 - SEC filing

BRIEF-BioScrip qtrly loss per share $0.26

* Q2 revenue $218.1 million versus I/B/E/S view $220.2 million

BRIEF-Ares Management reports 9.2 pct stake in Bioscrip

* Ares Management reports 9.2 pct stake in Bioscrip as of June 29 - SEC filing

BRIEF-BioScrip announces new senior note facilities

* BioScrip Inc - under agreement, company entered into a $200 million first lien note facility and a $110 million second lien note facility

BRIEF-Bioscrip provides update on Unitedhealthcare contract

* Bioscrip Inc - reached an agreement to continue to provide certain core product lines to unitedhealthcare beyond September 30, 2017

BRIEF-Bioscrip reports first quarter 2017 financial results

* Q1 revenue $217.8 million versus I/B/E/S view $229.7 million

BRIEF-Bioscrip Q4 loss per share $0.06

* Bioscrip reports fourth quarter and full-year 2016 financial results

BRIEF-Bioscrip reports third quarter 2016 financial results

* Bioscrip Inc- preliminary full year 2017 guidance is revenues in range of $940 million to $980 million

BRIEF-Bioscrip files for offering of up to 3.75 mln shares of common stock by the selling stockholder

* Files for offering of up to 3.75 million shares of common stock by the selling stockholder - sec filing Source text (http://bit.ly/2d9nVrl) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up